In MS mouse models, inducing this eIF2α phosphorylation-mediated adaptive capacity, either through genetic or pharmacological strategies, yields beneficial and protective effects in reducing EAE disease progression [27,29,30], plausibly driven by GCN2 activation. Here, EIF2AK4 is linked to myeloid sarcoma.